Provided by Tiger Trade Technology Pte. Ltd.

Corcept Therapeutics

34.04
-1.6500-4.62%
Post-market: 34.300.2600+0.76%19:53 EST
Volume:1.33M
Turnover:45.62M
Market Cap:3.62B
PE:41.51
High:35.55
Open:34.94
Low:33.85
Close:35.69
52wk High:117.33
52wk Low:28.66
Shares:106.37M
Float Shares:86.88M
Volume Ratio:0.78
T/O Rate:1.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.8200
EPS(LYR):0.8200
ROE:15.01%
ROA:3.34%
PB:5.59
PE(LYR):41.51

Loading ...

Corcept lower after Optime Care terminates distributor agreement for Korlym

TIPRANKS
·
Oct 10, 2025

Corcept Therapeutics falls -15.0%

TIPRANKS
·
Oct 10, 2025

Truist Financial Remains a Buy on Corcept Therapeutics (CORT)

TIPRANKS
·
Oct 10, 2025

Corcept Therapeutics Price Target Maintained With a $145.00/Share by HC Wainwright & Co.

Dow Jones
·
Oct 10, 2025

Corcept Therapeutics (CORT) Receives a Buy from H.C. Wainwright

TIPRANKS
·
Oct 10, 2025

Corcept Therapeutics Chief Development Officer William Guyer Reports Disposal of Common Shares

Reuters
·
Oct 10, 2025

Corcept Therapeutics Incorporated (NASDAQ:CORT) Stocks Shoot Up 30% But Its P/E Still Looks Reasonable

Simply Wall St.
·
Oct 07, 2025

Corcept Therapeutics Announces Resignation of Board Member Dr. Gillian Cannon; Enters Consulting Agreement Through 2026

Reuters
·
Oct 07, 2025

Corcept Therapeutics Officer Joseph Douglas Lyon Reports Disposal of Common Shares

Reuters
·
Oct 04, 2025

Corcept Therapeutics management to meet with Truist

TIPRANKS
·
Oct 02, 2025

4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals

Benzinga_recent_news
·
Sep 29, 2025

Corcept Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Sep 25, 2025

Canaccord Genuity Remains a Buy on Corcept Therapeutics (CORT)

TIPRANKS
·
Sep 25, 2025

Corcept Therapeutics to Present New Data from Pivotal ROSELLA Trial on Relacorilant for Platinum-Resistant Ovarian Cancer at ESMO 2025

Reuters
·
Sep 23, 2025

11 fast-growing small-cap stocks that could get a boost from the Fed's next move

Dow Jones
·
Sep 16, 2025

Drugmaker Corcept must face Teva lawsuit over mifepristone 'monopoly' for rare disorder

Reuters
·
Sep 15, 2025

Director Daniel N. Swisher Jr. Reports Disposal of Common Shares of Corcept Therapeutics Incorporated

Reuters
·
Sep 12, 2025

Corcept Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Sep 10, 2025

Corcept Therapeutics Inc : Canaccord Genuity Raises Target Price to $140 From $137

THOMSON REUTERS
·
Sep 10, 2025

FDA Accepts Corcept's New Drug Application for Relacorilant as Treatment for Platinum-Resistant Ovarian Cancer, PDUFA Date Set for July 2026

Reuters
·
Sep 10, 2025